News & Analysis on Clinical Trial Services & Contract Research And Development
Ex-Allergan CEO David Pyott has spoken of his “total war” battling Valeant’s failed hostile takeover, and given advice to other pharmaceutical companies on how to deal with activist shareholders.
|Dispatches from ACHEMA
EMA guidance on process validation for drugmakers is the latest update in cGMP regulations to manage a pharma world shifting from chemical to biological processing, says NNE Pharmaplan.
Swedish drugmaker Medivir has consolidated its drug discovery efforts though a deal with Indian CRO GVK Bio.
BIO 2015
Contract research organisation WuXi has entered a manufacturing collaboration with the University of Pennsylvania to produce gene therapy vectors.
Dispatches from ACHEMA 2015
The patent cliff and biopharmaceuticals have driven opportunities for pharma packaging companies, which say they are opting to grow through innovation rather than M&A.
Dispatches from DIA 2015
With more than 90% of revenue coming from pharma and biotech companies outside the top 25, CRO SynteractHCR is seeing more growth stemming from an influx of funding to smaller biotech companies, CEO Wendel Barr told us on the third day of the 51st annual...